Last updated: July 31, 2026
Myoview 30 mL is a technetium Tc 99m-labeled myocardial perfusion imaging product based on tetrofosmin. It is used with single-photon emission computed tomography, or SPECT, to assess myocardial perfusion in patients with suspected or known coronary artery disease. The product is a diagnostic radiopharmaceutical kit, not a therapeutic drug and not a biologic. Its commercial outlook depends mainly on nuclear cardiology procedure volume, hospital radiopharmacy access, technetium availability, reimbursement and competition from generic tetrofosmin and alternative imaging modalities.
No major late-stage therapeutic clinical-trial program is associated with Myoview. The product has long-standing FDA marketing authorization, and current clinical evidence is primarily post-approval diagnostic-performance, workflow and comparative-imaging research rather than registration trials.
What is Myoview 30 mL and how is it used?
Myoview contains tetrofosmin, a lipophilic technetium-99m complex used for myocardial perfusion imaging. The commercial kit is reconstituted with sodium pertechnetate Tc 99m before administration. The labeled indication covers rest and stress myocardial perfusion imaging in adults with suspected or established coronary artery disease.[1]
The product is used in two principal settings:
- Rest myocardial perfusion imaging.
- Stress imaging after exercise or pharmacologic stress.
Myoview is not administered as an unmodified 30 mL therapeutic dose. The relevant commercial presentation is the kit or vial configuration and the final prepared radiopharmaceutical volume, which varies according to site preparation, activity, concentration and institutional radiopharmacy practice. The radioactive product has a short effective commercial life because technetium-99m has a physical half-life of approximately six hours.[2]
Product profile
| Attribute |
Myoview |
| Active imaging agent |
Technetium Tc 99m tetrofosmin |
| Nonradioactive kit component |
Tetrofosmin formulation with reducing and stabilizing excipients |
| Therapeutic category |
Diagnostic radiopharmaceutical |
| Primary use |
Myocardial perfusion SPECT |
| Administration |
Intravenous |
| Typical clinical setting |
Hospital nuclear medicine and outpatient cardiology imaging |
| FDA status |
Approved diagnostic product |
| Primary manufacturer history |
Amersham and GE HealthCare lineage |
| Main competitors |
Sestamibi products, generic tetrofosmin products, PET myocardial perfusion agents |
| Major supply constraint |
Tc-99m availability and radiopharmacy logistics |
What is the FDA regulatory status of Myoview?
Myoview has FDA approval for myocardial perfusion imaging. The product is regulated as a drug and radiopharmaceutical, with preparation, quality-control, radiation-safety and administration requirements described in the prescribing information.[1]
The FDA label provides instructions for:
- Kit reconstitution.
- Use of sodium pertechnetate Tc 99m.
- Radiochemical purity testing.
- Dose preparation.
- Stress and rest imaging.
- Radiation exposure.
- Contraindications and precautions.
- Pregnancy, lactation and pediatric-use considerations.
Myoview is not a contrast-enhanced CT agent and is not a PET radiotracer. It belongs to the SPECT myocardial perfusion segment, where operational factors such as generator access, nuclear pharmacy schedules and same-day dose delivery materially affect utilization.
Are there active clinical trials for Myoview 30 mL?
Myoview does not have a conventional development program comparable with an investigational oncology, immunology or metabolic drug. Its clinical-trial activity is mainly associated with diagnostic comparison and imaging-method research.
Relevant study categories include:
- Comparison of tetrofosmin SPECT with technetium Tc 99m sestamibi.
- Comparison of SPECT with coronary angiography.
- Assessment of stress imaging protocols.
- Evaluation of attenuation correction and image reconstruction.
- Comparison of SPECT with PET myocardial perfusion imaging.
- Use of myocardial perfusion imaging in emergency-department chest-pain pathways.
- Imaging in women, patients with obesity and patients with prior coronary intervention.
ClinicalTrials.gov is the principal U.S. registry for ongoing and completed interventional studies. Searches for tetrofosmin and Myoview generally identify investigator-led diagnostic studies rather than sponsor-led registration trials.[3]
Clinical evidence position
The clinical value of Myoview is established through:
- Myocardial perfusion assessment.
- Detection of reversible ischemia.
- Risk stratification in patients with suspected coronary artery disease.
- Evaluation of perfusion after exercise or pharmacologic stress.
- Support for clinical decision-making regarding further coronary evaluation.
The product’s evidence base is mature. New studies are more likely to optimize patient selection, imaging protocols or comparative performance than to expand the core indication.
What patents protect Myoview and when does exclusivity expire?
The commercially relevant patent estate for Myoview is largely mature. Tetrofosmin and its use in myocardial perfusion imaging were developed decades ago. Core composition, formulation and diagnostic-use rights are unlikely to provide meaningful remaining exclusivity in the United States.
| IP category |
Current commercial relevance |
| Tetrofosmin chemical composition |
Core rights generally expired or commercially exhausted |
| Myocardial perfusion imaging use |
Long-standing rights; unlikely to block current generic entry |
| Kit formulation |
Potentially covered historically, but meaningful exclusivity is limited |
| Reconstitution process |
May be protected by historical or ancillary rights, subject to expiry |
| Manufacturing know-how |
Can remain confidential even after patent expiry |
| Radiopharmacy supply chain |
Operational barrier rather than patent exclusivity |
| Product branding |
Trademark protection can continue after patent expiry |
The principal entry barriers are not expected to be unexpired composition patents. They are manufacturing validation, regulatory approval, radiochemical quality control, supply reliability and hospital contracting.
Are there Paragraph IV challenges to Myoview?
A substantial current Paragraph IV controversy is not associated with Myoview in the public record through the latest established regulatory information. Any generic or abbreviated new drug application applicant would need to address the applicable listed patents, labeling and product-specific regulatory requirements.
For a mature radiopharmaceutical, a Paragraph IV filing would likely focus on:
- Noninfringement.
- Invalidity or unenforceability of listed patents.
- Design-around of formulation or kit claims.
- The absence of blocking patents.
- Product-specific manufacturing and quality controls.
The absence of a major current patent dispute reduces litigation-driven delay risk. It does not eliminate launch risk because radiopharmaceutical manufacturing and distribution are technically demanding.
What is the Orange Book status of Myoview?
Myoview is an FDA-approved prescription diagnostic product, and its regulatory status should be evaluated through the current FDA Drugs@FDA and Orange Book databases. Orange Book treatment can differ from conventional small-molecule tablets because radiopharmaceutical kits, labeling, manufacturing controls and product presentations do not map neatly onto standard generic-drug economics.[4]
Key regulatory points include:
- FDA approval is distinct from patent exclusivity.
- A product can remain commercially relevant after core patents expire.
- Generic competition may use an ANDA, a suitability pathway where applicable, or another FDA-approved route depending on product classification.
- A competing product must demonstrate pharmaceutical equivalence and adequate quality controls.
- Radioactive labeling and radiochemical purity add operational requirements beyond ordinary injectable generics.
How strong is the Myoview patent estate?
The Myoview patent estate is commercially weak as a long-term exclusivity platform because the product is mature and the central technology has been available for many years. Its defensibility is stronger in execution than in patent scope.
Patent-strength assessment
| Factor |
Assessment |
| Core composition protection |
Low remaining value |
| Method-of-use protection |
Limited incremental value |
| Formulation protection |
Potentially relevant but narrow |
| Manufacturing know-how |
Moderate operational value |
| Regulatory history |
High practical value |
| Brand recognition |
Moderate value in established accounts |
| Supply reliability |
High value because of radioactive shelf-life constraints |
| Switching costs |
Moderate at institutional level |
| Litigation exposure |
Low to moderate absent a new product-specific filing |
The strongest commercial moat is a validated supply chain that can consistently deliver radiopharmaceutical doses within the technetium-99m decay window.
What formulations and manufacturing methods are protected?
The product depends on a sterile kit formulation that can be reconstituted with Tc-99m pertechnetate. Manufacturing controls must preserve:
- Sterility.
- Radiochemical purity.
- Chemical stability.
- Correct ligand-to-metal coordination.
- Appropriate pH.
- Low levels of free technetium and reduced-hydrolyzed technetium.
- Consistent performance after reconstitution.
The product’s radioactive component is generally prepared close to the time of use. This creates manufacturing and distribution requirements that are more stringent than those for a conventional nonradioactive injectable.
Manufacturing barriers include:
- Access to qualified nuclear-pharmacy facilities.
- Validated sterile fill-finish operations.
- Radiation-shielded handling.
- Release testing.
- Generator or reactor-derived Tc-99m supply.
- Short-distance distribution capability.
- Stability data supporting the labeled shelf life.
These factors can delay or constrain competition even when patent barriers have expired.
How does Myoview compare with sestamibi and PET perfusion agents?
Myoview competes primarily with technetium Tc 99m sestamibi products, including generic sestamibi kits. It also competes indirectly with PET myocardial perfusion agents and stress echocardiography.
| Attribute |
Myoview |
Tc-99m sestamibi |
PET myocardial perfusion |
| Imaging modality |
SPECT |
SPECT |
PET |
| Isotope |
Tc-99m |
Tc-99m |
Rubidium-82, N-13 ammonia or other PET agents |
| Infrastructure |
Nuclear medicine camera and radiopharmacy |
Nuclear medicine camera and radiopharmacy |
PET or PET/CT and specialized supply |
| Availability |
Broad where Tc-99m is available |
Broad where Tc-99m is available |
More concentrated in advanced centers |
| Product maturity |
Long-established |
Long-established |
Growing but infrastructure-dependent |
| Typical economic position |
Established SPECT option |
Major SPECT alternative |
Higher-cost, higher-performance alternative in selected settings |
| Main differentiation |
Imaging performance, workflow and contracting |
Cost, availability and institutional familiarity |
Image quality, flow quantification and shorter protocols |
Sestamibi is the most direct competitive reference. The choice often depends on local price, contracting, image quality, preparation workflow and physician preference rather than on a clear universal clinical superiority claim.
PET has a stronger technical position in centers that can support it, especially where myocardial blood-flow quantification is valued. It has not displaced SPECT across the broader hospital market because equipment, tracer supply and capital requirements remain higher.
What is the market outlook for Myoview?
The addressable market is the global myocardial perfusion imaging market, with the largest commercial contribution from the United States, Europe and developed Asian markets. Demand is tied to:
- Coronary artery disease prevalence.
- Cardiology referral volume.
- Noninvasive ischemia testing guidelines.
- Availability of stress testing.
- Hospital nuclear-medicine capacity.
- Reimbursement.
- Competition from coronary CT angiography and PET.
The market is mature rather than high-growth. Myoview revenue is likely to track procedure volume and price realization, with growth limited by generic competition and substitution.
Market drivers
- Aging populations with coronary artery disease.
- Continued use of SPECT in community hospitals.
- Lower capital requirements than PET.
- Need for functional ischemia assessment in selected patients.
- Replacement demand for nuclear-medicine equipment.
- Expansion of outpatient diagnostic imaging.
Market restraints
- Generic pricing pressure.
- Coronary CT angiography substitution.
- PET adoption in tertiary centers.
- Tc-99m supply interruptions.
- Radiation exposure concerns.
- Reimbursement pressure.
- Declining use of some traditional preoperative testing pathways.
What are the revenue projections for Myoview?
Public, product-level revenue disclosure for Myoview is limited. A precise forecast cannot be derived from publicly reported company filings because the product is generally reported within broader pharmaceutical, diagnostic imaging or radiopharmaceutical portfolios.
A practical forecast uses a scenario model rather than a single point estimate.
| Scenario, 2025-2030 |
Procedure-volume assumption |
Net price assumption |
Revenue direction |
| Downside |
Decline of 3%-5% annually |
Decline of 4%-7% annually |
High-single-digit to low-double-digit annual decline |
| Base case |
Flat to 1% annual growth |
Decline of 2%-4% annually |
Low-single-digit to mid-single-digit annual decline |
| Upside |
Growth of 2%-3% annually |
Flat to decline of 1%-2% annually |
Flat to low-single-digit annual growth |
The base case assumes stable SPECT utilization, gradual generic erosion and modest migration to PET and coronary CT angiography. Myoview’s unit demand may remain resilient even as revenue declines because radiopharmaceutical prices can fall faster than procedure volume.
Which companies are challenging Myoview commercially?
The main competitive pressure comes from suppliers of:
- Generic tetrofosmin products.
- Tc-99m sestamibi kits.
- Other nuclear cardiology agents.
- PET myocardial perfusion tracers.
- Coronary CT angiography platforms.
- Stress echocardiography and cardiac MRI services.
Competitive intensity is highest in the United States, where hospital systems and group purchasing organizations can negotiate radiopharmaceutical pricing. In Europe, national reimbursement systems and centralized procurement have a larger effect. In emerging markets, availability of Tc-99m, nuclear-medicine infrastructure and local regulatory approvals are more important than patent protection.
What generic launch risks exist for Myoview?
A generic launch would most likely produce gradual, account-by-account erosion rather than an immediate market collapse. Hospitals may qualify more than one supplier, but switching can be limited by:
- Radiopharmacy validation.
- Existing purchasing contracts.
- Physician familiarity.
- Batch-release reliability.
- Dose delivery timing.
- Local reimbursement rules.
- Supply continuity.
The highest-risk commercial scenario is a reliable generic supplier offering lower pricing without compromising delivery. The lowest-risk scenario for the incumbent is a market with limited alternative suppliers and high hospital dependence on an established radiopharmacy network.
What litigation and settlement agreements affect Myoview?
No major active patent-litigation pattern is central to the commercial outlook of Myoview through the latest established public information. The product’s risk profile is more operational than litigation-driven.
Potential disputes could involve:
- ANDA patent challenges.
- Product-specific labeling.
- Manufacturing-process patents.
- Trade secrets relating to kit preparation.
- Supply agreements.
- Regulatory exclusivity claims.
- Distribution and hospital-contracting arrangements.
Settlement agreements would have commercial significance only if a new entrant challenged a still-listed patent or sought a negotiated launch date. The mature age of the product reduces the likelihood that historical patent settlements will control the current market.
Does Myoview face biosimilar risk?
No. Myoview is a small-molecule radiopharmaceutical kit, not a biologic. Biosimilar rules do not apply. Competitive entry is more likely to occur through generic-drug, radiopharmaceutical or other product-specific FDA pathways.
What is the geographic coverage of Myoview?
Myoview has historically been marketed across major developed pharmaceutical markets, subject to country-specific approvals, distributor arrangements and radiopharmacy infrastructure.
Commercial performance differs by geography:
- United States: strong regulatory and reimbursement influence; substantial generic and contracting pressure.
- Europe: national procurement and reimbursement determine market access.
- Japan: local regulatory and hospital-procurement requirements are important.
- Emerging markets: infrastructure and isotope availability often limit demand.
- Remote regions: short half-life and dose logistics can restrict distribution.
The product’s geographic reach is therefore narrower in practice than its regulatory footprint. A country may authorize the product but lack the nuclear-pharmacy network needed for broad use.
Key Takeaways
- Myoview 30 mL is a tetrofosmin-based Tc-99m myocardial perfusion imaging product.
- It is a mature diagnostic radiopharmaceutical, not a therapeutic drug or biologic.
- No major registration-stage clinical-trial program is associated with the product.
- Core patent protection is commercially mature, with limited expected remaining exclusivity.
- Paragraph IV and patent-litigation risk appear lower than manufacturing, supply and contracting risks.
- The main direct competitor is Tc-99m sestamibi; PET, coronary CT angiography and stress echocardiography create broader substitution pressure.
- The base-case outlook is stable-to-declining revenue because procedure volume is relatively resilient while generic pricing pressure increases.
- Manufacturing validation, Tc-99m access and reliable short-window distribution are the principal practical barriers to entry.
- Myoview has no biosimilar risk because it is not a biologic.
Frequently Asked Questions
Is Myoview the same as technetium Tc 99m tetrofosmin?
Myoview is the branded kit used to prepare technetium Tc 99m tetrofosmin for myocardial perfusion imaging. The radioactive final product is prepared by combining the kit with sodium pertechnetate Tc 99m.
Is Myoview still commercially relevant after patent expiry?
Yes. Radiopharmaceutical products can retain commercial value after patent expiry because validated manufacturing, radiopharmacy distribution, hospital contracting and reliable isotope supply affect purchasing decisions.
Can Myoview be replaced by coronary CT angiography?
In selected patients, coronary CT angiography can replace or precede functional testing. It does not eliminate the need for myocardial perfusion imaging in all patients, particularly where ischemia assessment, stress imaging or established nuclear-medicine workflows remain clinically appropriate.
What is the main supply risk for Myoview?
The main supply risk is the availability and timely delivery of Tc-99m, combined with the short half-life of the radioactive isotope. Manufacturing or transport delays can reduce usable inventory quickly.
Is Myoview a high-growth radiopharmaceutical?
No. Myoview is best characterized as a mature, cash-generating diagnostic product with limited organic growth. Its future performance is more likely to depend on retention, pricing, supply reliability and imaging-market stability than on clinical-trial expansion.
References
- U.S. Food and Drug Administration. (2023). Myoview kit for the preparation of technetium Tc 99m tetrofosmin injection: Prescribing information.
- International Atomic Energy Agency. (2022). Technetium-99m radiopharmaceuticals and nuclear medicine imaging.
- National Library of Medicine. (2024). ClinicalTrials.gov. https://clinicaltrials.gov/
- U.S. Food and Drug Administration. (2024). Drugs@FDA and Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.fda.gov/drugsatfda
